WALTHAM, Mass., Feb. 20, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases, will report fourth quarter and
fiscal year-end 2008 results, along with guidance for 2009, on Thursday,
February 26, 2009 . A conference call and webcast hosted by OXiGENE management
will begin at 4:30 pm EST (1:30 p.m. PST).
To listen to a live or an archived version of the audio webcast, please log on
to the Company's website, www.oxigene.com. Under the "Investors" tab, select
the link to "Events & Presentations."
OXiGENE's earnings conference call can also be heard live by dialing (877)
856-1965 in the United States and Canada, and (719) 325-4798 for international
callers, five minutes prior to the beginning of the call. A replay will be
available starting at 7:30 p.m. ET, (4:30 p.m. PST) on February 26, 2009 and
ending at 7:30 p.m. ET (4:30 p.m. PST) on Thursday, March 12, 2009. To access
the replay, please dial (888) 203-1112 if calling from the United States or
Canada, or (719) 457-0820 from international locations. Please refer to replay
pass code 2203249.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The company's major focus is
developing vascular disrupting agents (VDAs) that selectively disrupt abnormal
blood vessels associated with solid tumor progression and visual impairment.
OXiGENE is dedicated to leveraging its intellectual property and therapeutic
development expertise to bring life-extending and life-enhancing medicines to
patients.
The OXiGENE, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4969
CONTACT: OXiGENE, Inc.
Investor and Media Contact:
Michelle Edwards, Investor Relations
650-635-7006
medwards@oxigene.com
OXiGENE Announces Fourth Quarter and Fiscal 2008 Earnings Conference Call and Webcast
| Source: Nasdaq Stockholm AB